Schepart Alexander, Burton Arianna, Durkin Larry, Fuller Allison, Charap Ellyn, Bhambri Rahul, Ahmad Faraz S
Pfizer Inc, New York, New York.
VPMR LLC, Kennett Square, Pennsylvania.
Cardiovasc Digit Health J. 2023 May 3;4(3):101-110. doi: 10.1016/j.cvdhj.2023.04.003. eCollection 2023 Jun.
Numerous artificial intelligence (AI)-enabled tools for cardiovascular diseases have been published, with a high impact on public health. However, few have been adopted into, or have meaningfully affected, routine clinical care.
To evaluate current awareness, perceptions, and clinical use of AI-enabled digital health tools for patients with cardiovascular disease, and challenges to adoption.
This mixed-methods study included interviews with 12 cardiologists and 8 health information technology (IT) administrators, and a follow-on survey of 90 cardiologists and 30 IT administrators.
We identified 5 major challenges: (1) limited knowledge, (2) insufficient usability, (3) cost constraints, (4) poor electronic health record interoperability, and (5) lack of trust. A minority of cardiologists were using AI tools; more were prepared to implement AI tools, but their sophistication level varied greatly.
Most respondents believe in the potential of AI-enabled tools to improve care quality and efficiency, but they identified several fundamental barriers to wide-scale adoption.
众多用于心血管疾病的人工智能（AI）工具已发表，对公众健康产生了重大影响。然而，很少有工具被纳入常规临床护理或对其产生有意义的影响。
评估当前心血管疾病患者对人工智能驱动的数字健康工具的认知、看法和临床使用情况，以及采用过程中面临的挑战。
这项混合方法研究包括对12名心脏病专家和8名健康信息技术（IT）管理人员的访谈，以及对90名心脏病专家和30名IT管理人员的后续调查。
我们确定了5个主要挑战：（1）知识有限；（2）可用性不足；（3）成本限制；（4）电子健康记录互操作性差；（5）缺乏信任。少数心脏病专家正在使用人工智能工具；更多人准备实施人工智能工具，但他们的熟练程度差异很大。
大多数受访者相信人工智能工具具有提高护理质量和效率的潜力，但他们也指出了大规模采用的几个基本障碍。
